Navigation Links
Novel paclitaxel formulation encouraging for treating advanced lung cancer
Date:6/15/2010

The June edition of the Journal of Thoracic Oncology features a study aimed at determining the optimal dose of the chemotherapy drug nab-paclitaxel with carboplatin as a first-line therapy in patients with non-small cell lung cancer (NSCLC). Results will provide researchers with a data needed to guide a phase 3 trial.

The most commonly used combination treatment for patients with NSCLC is carboplatin plus solvent-based paclitaxel. However, this current treatment has major safety and efficacy concerns, such as severe toxicities, nerve damage. As lung cancer is the leading cause of lung cancer death worldwide, there is a critical need for safe chemotherapy treatments to curb this disease.

In this multi-center study, researchers sought to determine the optimal dose of a chemotherapy treatment using a novel paclitaxel formulation, nanoparticle albuminbound (nab-), which can be administered safely at higher doses than the solvent-based paclitaxel and has performed well when treating breast cancer patients. One hundred seventy-five previously untreated patients were enrolled in the study and received treatment with nab-paclitaxel either on a weekly or every-three-week basis. Dosing levels were also investigated.

Overall results showed response rate was greater in weekly doses than in every-three-week doses. Median progression-free survival was similar between both schedules and ranged from 4.8 to 6.9 months in the every-three-week cohorts and 5.6 to 6.4 months in the weekly cohorts. Overall survival was also similar in both groups and ranged from 8.3 to 14.6 months in the every-three-week cohort and 11.3 to 15.0 in the weekly cohort. Most favorable of all the cohorts was the group receiving 100 mg/m2 weekly nab-paclitaxel. This group achieved a 48 percent response rate with 6.2 and 11.3 months of progression-free survival and overall survival, respectively.

In addition to improved anti-tumor activity, nab-paclitaxel administered weekly was associated with less serious adverse events than when administered every three weeks, with significant reductions of nerve damage and muscle and joint pain. More specifically, it was found that a 100 mg/m2 weekly nab-paclitaxel produced less serious adverse events than other doses.

  Weekly dose  Every-three-week dose 
Response rate 47% 30%
ORR 36-56% 24-40%
 Progression-free survival  5.6-6.4 months 4.8-6.9 months
Overall survival  12.0-15.0 months  8.3-14.6 months

Researchers concluded that nab-paclitaxel plus carboplatin is an effective therapy for advanced NSCLC and recommend a phase 3, randomized, multi-center study comparison 100 mg/m2 weekly nab-paclitaxel plus carboplatin to solvent-based paclitaxel plus carboplatin.

"Given the high cumulative dose delivered and the excellent safety and efficacy profile of the patients who received 100 mg/m2 weekly nab-paclitaxel plus carboplatin, we believe this to be the optimal dosing and schedule for phase 3 comparison in patients with advanced NSCLC," confirms lead investigator Mark A. Socinski, MD of the University of North Carolina Lineberger Comprehensive Cancer Center.


'/>"/>

Contact: Megan Richter
mrichter@spectrumscience.com
202-587-2556
International Association for the Study of Lung Cancer
Source:Eurekalert

Related medicine news :

1. Novel Drug Combats Advanced Melanoma
2. Novel RNA interference screening technique identifies possible path for malignant glioma treatment
3. Novel anti-malarial drug candidate found by UT Southwestern researchers
4. ASCO data highlight novel anti-cancer approach that exposes tumors to immune attack
5. Research identifies patterns of CD24, a novel biomarker for non-small cell lung carcinomas
6. Third European Novel Food Approval Received by Tahitian Noni International
7. Novel nanoparticles prevent radiation damage
8. Novel soy germ-based dietary supplement, SE5-OH containing natural S-Equol, examined for safety and influence on hormones in pre- and post-menopausal women
9. Novel Method Eyed for Normalizing Blood Sugar
10. Novel Parkinson's Treatment Strategy Involves Cell Transplantation
11. MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic ... Frederick area economy by obtaining investment capital for emerging technology companies. SCP ... that have already resulted in more than a million dollars of capital investment ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a provider ... and other difficult to transfect cells, announces its launch of the PluriQ™ G9™ ... Editing System is a complete system for culturing and transfecting human pluripotent ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016 /PRNewswire/ ... pulmonary function testing company, is now able to perform sophisticated lung ... ndd Medical Technologies , Inc. Patients are ... labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients like ... any needed testing done in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
Breaking Medicine Technology: